Pionyr Immunotherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pionyr Immunotherapeutics, Inc.
Deal snapshot: Gilead’s latest significant cancer deal brings it a CCR8 binder, a novel preclinical immunotherapy, while Jounce finds a new deep-pocketed partner after the termination of its collaboration with Celgene.
- Large Molecule
- Other Names / Subsidiaries
- Gilead Sciences, Inc.